RANI (Rani Therapeutics Holdings) Retained Earnings: $-139.61 Mil (As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
31 GF Score
Price $0.69
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Retained Earnings?

Rani Therapeutics Holdings RANI -1.58% 31 Retained Earnings is $-139.61 Mil as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Rani Therapeutics Holdings's retained earnings for the quarter that ended in Mar. 2026 was $-139.61 Mil.

Rani Therapeutics Holdings's quarterly retained earnings declined from Sep. 2025 ($-122.28 Mil) to Dec. 2025 ($-132.58 Mil) and declined from Dec. 2025 ($-132.58 Mil) to Mar. 2026 ($-139.61 Mil).

Rani Therapeutics Holdings's annual retained earnings declined from Dec. 2023 ($-72.89 Mil) to Dec. 2024 ($-102.91 Mil) and declined from Dec. 2024 ($-102.91 Mil) to Dec. 2025 ($-132.58 Mil).


Rani Therapeutics Holdings  (NAS:RANI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Rani Therapeutics Holdings Retained Earnings Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Retained Earnings Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -8.33 -38.92 -72.89 -102.91 -132.58

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -110.17 -116.86 -122.28 -132.58 -139.61
RANI
31GF Score
Rani Therapeutics Holdings Inc RANI
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-139.61 Mil mean?
Rani Therapeutics Holdings (RANI) has a Retained Earnings of $-139.61 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' Retained Earnings too high?
Rani Therapeutics Holdings' current Retained Earnings is $-139.61 Mil. Overall, Rani Therapeutics Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Retained Earnings compare to IBIO and RNTX?
Rani Therapeutics Holdings' Retained Earnings of $-139.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current Retained Earnings is $-139.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Retained Earnings of $-139.61 Mil. The current Retained Earnings is $-139.61 Mil. Rani Therapeutics Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Retained Earnings is $-139.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
31GF Score

Get the complete analysis for RANI

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.69
Price